Autonomix Medical can sell up to $10.525 million of common stock through Ladenburg, acting as sales agent or principal. The proceeds are intended for Working Capital and general corporate purposes, while the amount raised will depend on shares sold and market prices, with no assurance the company will fully use the agreement.
Key Highlights
- Autonomix Medical is authorized to issue 500,000,000 shares of common stock.
- The company’s outstanding common stock base was 1,959,938 shares as of September 8, 2026.
- Net proceeds are earmarked for working capital and general corporate purposes, with management retaining broad discretion.
Autonomix Medical, Inc. (NASDAQ: AMIX) can raise up to $10.525 million by selling common stock through Ladenburg Thalmann & Co. Inc. The sales may occur from time to time through an at-the-market arrangement or in privately negotiated transactions. Ladenburg may act as the company’s sales agent or principal. The amount raised will depend on the number of shares sold and the Market Price at the time of each sale.
ATM Offering Sets $10.525M Ceiling
The common-stock offering has an aggregate sales limit of up to $10.525 million before sales-agent commissions and expenses. The company’s common stock trades on the Nasdaq Capital Market under AMIX. Sales can be made through Ladenburg under the existing ATM Agreement. The terms also permit privately negotiated sales alongside transactions conducted at market prices. The company’s authorized common stock totals 500,000,000 shares. Its outstanding common stock base was 1,959,938 shares as of September 8, 2026.
Capital Structure Includes Warrants
The share count used for the offering-related calculation excludes outstanding Options and warrants. The company is authorized to issue common stock beyond its current outstanding base, subject to the total authorized number of shares.
Proceeds Target Corporate Needs
Autonomix Medical intends to direct net proceeds to working capital and general corporate purposes. The company has not allocated specific amounts to those categories. Management will have broad discretion over how the net proceeds are applied. The company says it cannot predict whether those investments will produce a favorable return or any return. Actual spending amounts and timing will depend on numerous factors.
Sales Volume Remains Open
Autonomix Medical may sell shares under the arrangement, but the proceeds will depend on both sales volume and the market price at which transactions occur. The company states that it may not sell any shares or fully use the ATM Agreement. The common stock closed at $4.58 per share on September 8, 2026, as reported on NASDAQ. That figure is the reported closing price and is not identified as a fixed offering price. The company says investing in its securities involves a high degree of risk. It also says that if identified risks occur, its Business could be harmed, the trading price of its common stock could decline, and investors could lose all or part of their investment. Autonomix Medical has never declared or paid cash dividends on its Capital Stock and does not currently intend to pay cash dividends on its common stock for the foreseeable future.




Please wait processing your request...